Etavopivat tablets

DRUG2 trials

Sponsors

Forma Therapeutics, Inc.

Conditions

Sickle Cell DiseaseThalassemia

Phase 2

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

CompletedNCT04987489

Forma Therapeutics, Inc.Sickle Cell Disease, Thalassemia

Start: 2022-03-28End: 2025-09-24Updated: 2025-12-16

Phase 3

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

Active, not recruitingNCT04624659

Forma Therapeutics, Inc.Sickle Cell Disease

Start: 2021-01-29End: 2027-03-19Target: 450Updated: 2026-04-06

Related Papers

Etavopivat Reduces Incidence of Vaso-occlusive Crises in Patients With Sickle Cell Disease: Hibiscus Trial Phase 2 Results through 52 Weeks

Journal of sickle cell disease.2025-06-01

Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks

Blood2024-11-052 citations

Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease

Blood Advances2024-04-1917 citations

Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease

Blood2023-11-02

PB2524: TRIAL IN PROGRESS: THE HIBISCUS-KIDS STUDY, A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF ETAVOPIVAT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE

HemaSphere2023-08-011 citations

O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH

HemaSphere2022-08-012 citations

P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE

HemaSphere2022-08-01

P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH

HemaSphere2022-06-012 citations

PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE

HemaSphere2022-06-01

Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial

Clinical Pharmacology in Drug Development2022-01-1227 citations

S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE

HemaSphere2022-01-012 citations

S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS

HemaSphere2022-01-011 citations

Activation of Pyruvate Kinase-R with Etavopivat (FT-4202) Is Well Tolerated, Improves Anemia, and Decreases Intravascular Hemolysis in Patients with Sickle Cell Disease Treated for up to 12 Weeks

Blood2021-11-058 citations

Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease

Blood2021-11-054 citations